GSK makes deal worth up to $2.2B for Parkinson’s, Alzheimer’s drugs
GlaxoSmithKline is committing up to $2.2 billion for potential drugs to treat Parkinson’s and Alzheimer’s as well as other diseases in a deal announced Friday with drug firm Alector.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
